Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
Ryan Allway May 26th, 2022 News, Top News The Company received positive comments from the FDA to determine potential new clinical endpoints to support Emergency Use Authorization TORONTO, May 26, 2022 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty... Read more
( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )